Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2007

01.08.2007 | Original Paper

Expression of estrogen receptor β wt isoform (ERβ1) and ERβΔ5 splice variant mRNAs in sporadic breast cancer

verfasst von: Vesna Mandušić, Dragica Nikolić-Vukosavljević, Nikola Tanić, Ksenija Kanjer, Zora Neškovic-Konstantinović, Dušica Čeleketić, Bogomir Dimitrijević

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In addition to Estrogen Receptor α (ERα) and Progesterone Receptor (PR), the Second Estrogen Receptor (ERβ) appears to play an important role not only in estrogen signaling, but also in the pathogenesis of cancer in estrogen dependent tissues. The existence of various isoforms and splice variants of both ERs additionally complicates elucidation of their physiological role and involvement in the process of carcinogenesis.

Methods

In this study, the expression of ERβ1 mRNA (wild type of β receptor) and splice variant ERβΔ5 mRNA (which codes for truncated protein) was measured by the quantitative RT-PCR (q RT-PCR) in the 60 samples of Breast Cancer (BC) and correlated with ERα and PR protein levels and with clinical and histopathological parameters.

Results

We found the inverse correlation of ERβΔ5 mRNA expression with the levels of PR and ERα proteins in the group of postmenopausal patients; we also report the lower expression of ERβ1 and ERβΔ5 mRNA in the larger tumors (>20 mm, T2, and T3) than in smaller ones (≤20 mm, T1). The decrease of ERβΔ5 mRNA expression in larger tumors is found to arise from ER-positive breast carcinomas. In addition, the portion of tumors with concomitant high expression of both transcripts matches up the known percentage of tumors resistant to endocrine therapy in patients with different ER/PR status.

Conclusions

As far as we know, this is the first study in which ERβΔ5 mRNA splice variant was quantified by real-time RT-PCR in the clinical samples of breast cancer tissue. Until now, the focus of clinical reports was the level of ERβ1, ERβ2, and ERβ5 isoforms. The higher expression of ERβΔ5 mRNA is associated with the indicators of low biological aggressiveness of tumor (low tumor size within ER-positive status in our study) suggesting that the uncontrolled local tumor growth may occur as the expression of ERβΔ5 mRNA decreases in estrogen-dependent breast cancer.
Literatur
Zurück zum Zitat Ariazi EA, Clark GM, Mertz JE (2002) Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62:6510–6518PubMed Ariazi EA, Clark GM, Mertz JE (2002) Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62:6510–6518PubMed
Zurück zum Zitat Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11:537–551PubMedCrossRef Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11:537–551PubMedCrossRef
Zurück zum Zitat Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54:105–112PubMed Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54:105–112PubMed
Zurück zum Zitat Bollig A, Miksicek RJ (2000) An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol 14:634–649PubMedCrossRef Bollig A, Miksicek RJ (2000) An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol 14:634–649PubMedCrossRef
Zurück zum Zitat Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T, Pujol P (2001) Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer. Int J Cancer 95:205–208PubMedCrossRef Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T, Pujol P (2001) Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer. Int J Cancer 95:205–208PubMedCrossRef
Zurück zum Zitat Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, Piao YS, Gustafsson JA (2005) Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 90:435–444PubMedCrossRef Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, Piao YS, Gustafsson JA (2005) Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 90:435–444PubMedCrossRef
Zurück zum Zitat Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159PubMedCrossRef Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159PubMedCrossRef
Zurück zum Zitat EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 9:1513–1515 EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 9:1513–1515
Zurück zum Zitat Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H (2004) Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776PubMedCrossRef Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H (2004) Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769–5776PubMedCrossRef
Zurück zum Zitat Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425–5428PubMed Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT (1999) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 59:5425–5428PubMed
Zurück zum Zitat Girault I, Andrieu C, Tozlu S, Spyratos F, Bieche I, Lidereau R (2004) Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett 215:101–112PubMedCrossRef Girault I, Andrieu C, Tozlu S, Spyratos F, Bieche I, Lidereau R (2004) Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett 215:101–112PubMedCrossRef
Zurück zum Zitat Hall JM, McDonnell DP (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578PubMedCrossRef Hall JM, McDonnell DP (1999) The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578PubMedCrossRef
Zurück zum Zitat Hirata S, Shoda T, Kato J, Hoshi K (2001) The multiple untranslated first exons system of the human estrogen receptor beta (ER beta) gene. J Steroid Biochem Mol Biol 78:33–40PubMedCrossRef Hirata S, Shoda T, Kato J, Hoshi K (2001) The multiple untranslated first exons system of the human estrogen receptor beta (ER beta) gene. J Steroid Biochem Mol Biol 78:33–40PubMedCrossRef
Zurück zum Zitat Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10:7490–7499PubMedCrossRef Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10:7490–7499PubMedCrossRef
Zurück zum Zitat Inoue S, Ogawa S, Horie K, Hoshino S, Goto W, Hosoi T, Tsutsumi O, Muramatsu M, Ouchi Y (2000) An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERbeta. Biochem Biophys Res Commun 279:814–819PubMedCrossRef Inoue S, Ogawa S, Horie K, Hoshino S, Goto W, Hosoi T, Tsutsumi O, Muramatsu M, Ouchi Y (2000) An estrogen receptor beta isoform that lacks exon 5 has dominant negative activity on both ERalpha and ERbeta. Biochem Biophys Res Commun 279:814–819PubMedCrossRef
Zurück zum Zitat Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S (2000) Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 88:733–736PubMedCrossRef Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S (2000) Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 88:733–736PubMedCrossRef
Zurück zum Zitat Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98:15197–15202PubMedCrossRef Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98:15197–15202PubMedCrossRef
Zurück zum Zitat Lazennec G (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 231:151–157PubMedCrossRef Lazennec G (2006) Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 231:151–157PubMedCrossRef
Zurück zum Zitat Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC, Watson PH (1998) Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 138:199–203PubMedCrossRef Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC, Watson PH (1998) Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol 138:199–203PubMedCrossRef
Zurück zum Zitat Miyoshi Y, Taguchi T, Gustafsson JA, Noguchi S (2001) Clinicopathological characteristics of estrogen receptor-beta-positive human breast cancers. Jpn J Cancer Res 92:1057–1061PubMed Miyoshi Y, Taguchi T, Gustafsson JA, Noguchi S (2001) Clinicopathological characteristics of estrogen receptor-beta-positive human breast cancers. Jpn J Cancer Res 92:1057–1061PubMed
Zurück zum Zitat Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75–78PubMedCrossRef
Zurück zum Zitat Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R (2005) Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34:553–566PubMedCrossRef Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R (2005) Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34:553–566PubMedCrossRef
Zurück zum Zitat Nilsen J, Mor G, Naftolin F (2000) Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 43:64–78PubMedCrossRef Nilsen J, Mor G, Naftolin F (2000) Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 43:64–78PubMedCrossRef
Zurück zum Zitat Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26:3505–3512PubMedCrossRef Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26:3505–3512PubMedCrossRef
Zurück zum Zitat Ohlsson H, Lykkesfeldt AE, Madsen MW, Briand P (1998) The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1. Cancer Res 58:4264–4268PubMed Ohlsson H, Lykkesfeldt AE, Madsen MW, Briand P (1998) The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1. Cancer Res 58:4264–4268PubMed
Zurück zum Zitat Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508–1510PubMedCrossRef Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277:1508–1510PubMedCrossRef
Zurück zum Zitat Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, Lee KS (2006) The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93:504–510PubMedCrossRef Park BW, Kim KS, Heo MK, Yang WI, Kim SI, Kim JH, Kim GE, Lee KS (2006) The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development. J Surg Oncol 93:504–510PubMedCrossRef
Zurück zum Zitat Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef
Zurück zum Zitat Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45PubMedCrossRef
Zurück zum Zitat Poola I, Abraham J, Baldwin K (2002) Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett 516:133–138PubMedCrossRef Poola I, Abraham J, Baldwin K (2002) Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett 516:133–138PubMedCrossRef
Zurück zum Zitat Poola I, Abraham J, Liu A (2002) Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J Steroid Biochem Mol Biol 82:169–179PubMedCrossRef Poola I, Abraham J, Liu A (2002) Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. J Steroid Biochem Mol Biol 82:169–179PubMedCrossRef
Zurück zum Zitat Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A (2005) Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 11:7579–7585PubMedCrossRef Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A (2005) Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 11:7579–7585PubMedCrossRef
Zurück zum Zitat Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541PubMed
Zurück zum Zitat Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853PubMed Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853PubMed
Zurück zum Zitat Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA (2002) Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 198:450–457PubMedCrossRef Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA (2002) Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J Pathol 198:450–457PubMedCrossRef
Zurück zum Zitat Shoda T, Hirata S, Kato J, Hoshi K (2002) Cloning of the novel isoform of the estrogen receptor beta cDNA (ERbeta isoform M cDNA) from the human testicular cDNA library. J Steroid Biochem Mol Biol 82:201–208PubMedCrossRef Shoda T, Hirata S, Kato J, Hoshi K (2002) Cloning of the novel isoform of the estrogen receptor beta cDNA (ERbeta isoform M cDNA) from the human testicular cDNA library. J Steroid Biochem Mol Biol 82:201–208PubMedCrossRef
Zurück zum Zitat Speirs V (2002) Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J Pathol 197:143–147PubMedCrossRef Speirs V (2002) Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J Pathol 197:143–147PubMedCrossRef
Zurück zum Zitat Speirs V, Adams IP, Walton DS, Atkin SL (2000) Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J Clin Endocrinol Metab 85:1601–1605PubMedCrossRef Speirs V, Adams IP, Walton DS, Atkin SL (2000) Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. J Clin Endocrinol Metab 85:1601–1605PubMedCrossRef
Zurück zum Zitat Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL (1999) Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59:5421–5424PubMed Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL (1999) Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59:5421–5424PubMed
Zurück zum Zitat Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R (2002) Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 71:249–255PubMedCrossRef Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R (2002) Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 71:249–255PubMedCrossRef
Zurück zum Zitat User Bulletin #2 (2001) Comparative CT method: Applied Biosystems. http://docs.appliedbiosystems.com/pebiodocs/04303859.pdf#search=%22user%20bulletin%202%20abi%22. Cited 3 Oct 2006 User Bulletin #2 (2001) Comparative CT method: Applied Biosystems. http://​docs.​appliedbiosystem​s.​com/​pebiodocs/​04303859.​pdf#search=%22user%20bulletin%202%20abi%22. Cited 3 Oct 2006
Zurück zum Zitat Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R (1998) Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 58:210–214PubMed Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R (1998) Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 58:210–214PubMed
Metadaten
Titel
Expression of estrogen receptor β wt isoform (ERβ1) and ERβΔ5 splice variant mRNAs in sporadic breast cancer
verfasst von
Vesna Mandušić
Dragica Nikolić-Vukosavljević
Nikola Tanić
Ksenija Kanjer
Zora Neškovic-Konstantinović
Dušica Čeleketić
Bogomir Dimitrijević
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-007-0209-x

Weitere Artikel der Ausgabe 8/2007

Journal of Cancer Research and Clinical Oncology 8/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.